Jasmeet Singh to Dose-Response Relationship, Drug
This is a "connection" page, showing publications Jasmeet Singh has written about Dose-Response Relationship, Drug.
Connection Strength
0.104
-
Holden DN, Dingman JS, Sutton LH, Ramos-Estebanez C, El Ammar F, Warinpramote J, Siddiqui R, Choi R, Schneider L, Baker R, Bonderski V, Morsi RZ, Desai H, Kass-Hout T, Singh J, Kuhn AL, Puri AS, Gutierrez-Aguirre SF, Hanel RA, Zaidat OO, Ashouri Y, AlMajali M, Anderson E, Wetmore L, Barats M, Kimmons L, Scott W, Webb A, Johnson R, O'Donnell JN, Entezami P. Multicenter evaluation of the safety and efficacy of varying doses of cangrelor used in acute cerebrovascular stenting in patients with acute ischemic stroke. J Neurointerv Surg. 2026 Apr 16; 18(5):1372-1377.
Score: 0.052
-
Johnson ML, Patel MR, Falchook GS, Koyama T, Gutierrez M, Awad MM, Piha-Paul SA, Friedman CF, Satoh T, Okamoto N, Singh J, Yoshizuka N, Windish HP, Qian M, Tran BP, Doi T. Ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial. Lancet Oncol. 2026 Apr; 27(4):491-501.
Score: 0.052